Wolverine Stack
Protocol Guide
The Wolverine Stack combines BPC-157 and TB-500 in a single research protocol — targeting both local tissue repair (BPC-157 via the FAK-paxillin pathway) and systemic wound healing (TB-500 via actin regulation and angiogenesis). The complementary mechanisms make this one of the most studied stacks in peptide research.
What is Wolverine Stack?
BPC-157 and TB-500 complement each other through distinct, non-overlapping mechanisms. BPC-157 activates local signalling — FAK-paxillin for fibroblast migration, VEGFR2 for local angiogenesis, and direct gut cytoprotection. TB-500 acts systemically through actin sequestration, promoting cell migration and blood vessel formation throughout the body.
The rationale for combining them: BPC-157 provides targeted, localised activity at the injury site (especially effective when injected nearby), while TB-500's systemic reach can improve healing across multiple tissues simultaneously. Animal models suggest the combination may produce additive effects on tissue repair markers compared to either compound alone — human data remains limited.
Dosing Schedule
Parameters documented in published preclinical and clinical research.
| Phase | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| BPC-157 | 250–500 mcg | Once or twice daily | 4–6 weeks | Published protocols have used sites proximal to target tissue or abdomen. Daily administration sustains local signalling in research models. |
| TB-500 — Loading weeks 1–4 | 5–10 mg | Twice weekly | 4 weeks | Higher loading dose phase documented in published protocols. |
| TB-500 — Maintenance | 2.5–5 mg | Once or twice weekly | Weeks 5–6+ | Reduced dose phase per published maintenance protocols. |
| Off cycle | — | — | 4 weeks | Full rest from both compounds before next research cycle. |